Positive selection of CD56+ lymphocytes by magnetic cell sorting

Natural Immunity

Volumn 15, Issue 5, 1997, Pages 227-233

  Geiselhart, Andreas ^a   Neu, Stefan ^a   Buchholz, Frank ^a   Lang, Peter ^a   Niethammer, Dietrich ^a   Handgretinger, Rupert ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cd56; Immunomagnetic separation; Natural killer cells; Selection, positive; T cells

Indexed keywords

CD56 ANTIGEN; INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ARTICLE; CELL SELECTION; CELL SEPARATION; CELL SORTER; HUMAN; HUMAN CELL; NORMAL HUMAN; T LYMPHOCYTE;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD56; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; GOATS; HUMANS; IMMUNOMAGNETIC SEPARATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MICE;

EID: 9844246979     PISSN: 10188916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Timonen T, Ortaldo JR, Herberman RB: Characteristics of human large granular lymphocytes and relationship to natural killer and k cells. J Exp Med 1981;153:569-582.
2. Lanier LL, Testi R, Bimdl J, Phillips JH: Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989;169:2233-2238.
3. Lanier LL, Le AM , Civin CI, Loken MR, Phillips JH: The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-4486.
4. Schmidt-Wolf GH, Negrin R, Kiem H-P, Blume KG, Irving L, Weissman: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174:139-149.
5. Lu PH, Negrin RS: A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mice (abstract). Blood 1993;82:736.
6. Itoh K, Tilden AB, Balch CM: Lysis of human solid tumors by lymphokine-activated natural killer cells. J Immunol 1989;136:3183-3191.
7. Lotzova E, Sabary CA, Herberman RB: Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J Immunol 1987;138:2718-2727.
8. Miltenyi S, Müller W, Weichel W, Radbruch A: High gradient magnetic cell separation with MACS. Cytometry 1990;11:231.
9. Timonen T, Reynolds CW, Ortaldo JR, Herberman RB: Isolation of human and rat natural killer cells. J Immunol Methods 1982;51:269.
10. Zarling JM, Clouse KA, Biddison WE, Kung PC: Phenotypes of human natural killer cell population detected with monoclonal antibodies. J Immunol 1981;127:2575.
11. Handgretinger R, Kimmig A, Lang P, Daurer B, Kuci S, Bruchelt G, Treuner J, Niethammer D: Interferon-gamma upregulates the susceptibility of human neuroblastoma cells to interleukin-2-activated natural killer cells. Nat Immun 1989;8:189-196.
12. Lanier LL, Le AM, Phillips HG, Warner NL, Babcock GR: Subpopulation of human natural killer cells defined by expression of Leu-7 (HNK-1) and Leu-11 (NKKP-15) antigens. J Immunol 1983;131: 1789-1796.
13. bright subset. J Clin Lab Anal 1994;8:443-446.
14. Lu PH, Negrin RS: A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153/4:1687-1697.
15. Vujanovic NL, Rabinowich H, Lee YJ, Jost L, Herberman RB, Whiteside TL: Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin-2 induce adherence to plastic. Cell Immunol 1993;151: 133-157.
16. Basse PH, Goldfarb RH, Herberman RB, Hokland ME: Accumulation of adoptively transferred ANK cells in murine metastases: Kinetics and role of interleukin-2. In Vivo 1994;8:17-24.
17. Vujanovic NL, Yasumura S, Hirabayashi H, Lin WC, Watkins S, Herberman RB, Whiteside TL: Antitumor activities of human IL2-activated natural killer cells in solid tumor tissues. J Immunol 1995;154: 281-289.
18. Kuppen RJK, Basse PH, Goldfarb RH, Van De Velde CJH, Fleuren GJ, Eggermont AMM: The infiltration of experimentally-induced lung metastases of colon carcinoma CC531 by adoptively-transferred interleukin 2 activated natural killer cells in Wag rats. Int J Cancer 1994; 56:574-579.
19. Yasumura S, Lin W, Hirabayashi H, Vujanovic NL, Herberman RB, Whiteside TL: Immunotherapy of liver metastases of human gastric carcinoma with IL-2 activated natural killer cells. Cancer Res 1994;54: 3808-3816.
20. Lister J, Rybka WB, Donnenberg AD, DeMagalhaes-Silverman M, Pincus SM, Blomm EJ, Elder EM, Ball ED, Whiteside TL: Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with A-NK cells in the immediate post-transplant period. Clin Cancer Res 1995;1:607-614.
21. Bernstein ZP, Vaickus L, Friedman N, Goldrosen MH, Watanabe H, Rahman R, Arbuck SG, Sweeney J, Vesper D, Henderson ED, Zeffren J, Dennin RA, Levitt D, Foon KA: Interleukin 2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease. J Immunother 1991;10:141-146.
22. Grimm EA, Ramsay KM, Mazumber A, Wilson DJ, Djeu JY, Rosenberg SA: Lymphokine activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus derived lymphocytes and natural killer cells. J Exp Med 1993;157:884-897.
23. Rosenberg SA, Lotze MT, Muul LM: A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987;316:889-897.